Compare Moderna, Inc. (MRNA) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Prospect Capital Corporation — how do they compare? Moderna, Inc. trades at $60.83 (market cap $24.18B), while Prospect Capital Corporation trades at $2.27 (market cap $1.14B). The key difference: Moderna, Inc. is far larger — about 21.2× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 21.93% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | PSEC | |
|---|---|---|
Market Cap | $24.18B | $1.14B |
Sector | Health | Financials |
52-Week High | $81.80 | $3.05 |
52-Week Low | $22.36 | $2.11 |
Enterprise Value | $20.33B | — |
Dividend Yield | — | 21.93% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
